Inst. Holders
39 funds
SGMO
SANGAMO THERAPEUTICS, INC
—
12-mo target$1.50 (+1927.0%)
Insider Selling Cluster (2 insiders)High Impact Filing (9/10)8 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on SGMO right now — valuation, ownership and activity at a glance.
Inst. Value
$9.1M
Inst. Activity
8 buys / 2 sells
Insider Activity
$0.00 buy / $106.9K sell
Insider Net $
-$106.9K
SEC Reports
3
Press Releases
2
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 11, 2026 earnings_calendar
Jul 1, 2026 SEC SGMO Q2 2026 Earnings After Market Close — 2026-08-11
Sangamo Therapeutics filed an 8-K disclosing the termination of Ernst & Young as its independent auditor following its C
8-K — Impact 9/10
May 25, 2026 Insider
Davis Gregory D surrendered for taxes 1,630 shares
Head of Research & Technology @ $0.1743 ($284.11)
May 25, 2026 Insider
Jain Nikunj surrendered for taxes 1,919 shares
Principal Accounting Officer @ $0.1743 ($334.48)
May 25, 2026 Insider
Apr 29, 2026 SEC Dubois-Stringfellow Nathalie surrendered for taxes 4,036 shares
SVP-CHIEF DEVELOPMENT OFFICER @ $0.1743 ($703.47)
Sangamo Therapeutics received a delisting notice from Nasdaq on April 28, 2026, due to its stock price remaining below $
8-K — Impact 8/10
Two senior executives at Sangamo Therapeutics — the Chief Development Officer and Head of Research & Technology — sold s
CLUSTER — Impact 3/10
Mar 31, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
3,836,665 shares ($947.3K)
Analyst ratings buy % +28.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Nov 7, 2025 | Barclays | DOWNGRADE | Equal-Weight | 54% |
| Sep 4, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 24, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 14, 2025 | Barclays | MAINTAIN | Overweight | 54% |
| Apr 7, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Mar 18, 2025 | RBC Capital | REITERATE | Sector Perform | 55% |
| Jan 27, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jan 23, 2025 | Truist Securities | MAINTAIN | Buy | 55% |
| Jan 2, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Aug 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jul 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| May 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Feb 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% |
Price targets
Where 2 covering analysts think SGMO trades over the next 12 months.
$1.50 +1927.0% upside Strong Buy
Current$0.0740 Low$1.00 Median$1.50 High$2.00 2 analysts
$1.00$2.00
Analyst rating Buy· 2.0/5 as of Aug 29, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 1 neutral · avg impact 6.7/10.Plus 2 press releases.
BEARISH8-K9/10
Sangamo Therapeutics filed an 8-K disclosing the termination of Ernst & Young as its independent aud
Jul 1, 2026
BEARISH8-K8/10
Sangamo Therapeutics received a delisting notice from Nasdaq on April 28, 2026, due to its stock pri
Apr 29, 2026
NEUTRALCLUSTER3/10
Two senior executives at Sangamo Therapeutics — the Chief Development Officer and Head of Research &
Apr 23, 2026
MIXED6/10
Sangamo Therapeutics reported mixed financial results for 2025, with declining annual revenue and wi
Mar 30, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 11, 2026
earnings_calendar
SGMO Q2 2026 Earnings After Market Close — 2026-08-11
Jul 6, 2026
Clinical Trial
Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
Phase Phase 2 — COMPLETED
May 18, 2026
earnings_calendar
SGMO Q1 2026 Earnings After Market Close — 2026-05-18
May 14, 2026
earnings_calendar
SGMO Q1 2026 Earnings After Market Close — 2026-05-14
May 4, 2026
short_volume
Short Volume: SGMO — 60.8% short (36.0M / 59.2M)
Short: 35,977,841 | Exempt: 556,482 | TRF Vol: 59,178,414 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.07 | $-0.07–$-0.07 | 12.5% | -16.7% | 1↑ 0↓ | $0.0B | 1 |
| Current FY | $-0.30 | $-0.30–$-0.30 | 23.4% | -20.0% | 1↑ 0↓ | $0.0B | 1 |
| Next Q | $-0.08 | $-0.08–$-0.08 | 27.3% | -23.1% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $-0.10 | $-0.10–$-0.10 | 66.7% | -2100.0% | 1↑ 0↓ | $0.1B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.070 | — |
| 7d ago | $-0.060 | -0.010 |
| 30d ago | $-0.060 | -0.010 |
| 60d ago | $-0.065 | -0.005 |
| 90d ago | $-0.040 | -0.030 |
Institutional ownership
Which big funds own SGMO (from quarterly 13F filings) and who is adding or trimming.
39 institutional holders with $9.1M total value (36,837,581 shares) as of 2026-Q1. Top holders: BARCLAYS, TWO, BALYASNY. Net buying activity: 8 institutions added/increased vs 2 reduced.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BARCLAYS PLC | 1 | $0.00 | 0.0% | — |
| TWO SIGMA INVESTMENTS, LP | 6,270,441 | $1.5M | 17.0% | ADD +91.8% |
| BALYASNY ASSET MANAGEMENT L.P. | 5,288,097 | $1.3M | 14.3% | — |
| BlackRock, Inc. | 4,547,848 | $1.1M | 12.3% | — |
| RENAISSANCE TECHNOLOGIES LLC | 3,836,665 | $947.3K | 10.4% | TRIM -54.5% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,352,360 | $580.8K | 6.4% | ADD +37.3% |
| VANGUARD FIDUCIARY TRUST CO | 2,310,297 | $570.6K | 6.3% | — |
| BANK OF AMERICA CORP /DE/ | 1,838,390 | $452.2K | 5.0% | DOUBLED +1856.1% |
| STATE STREET CORP | 1,694,783 | $418.4K | 4.6% | ADD +25.0% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,687,463 | $416.6K | 4.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 8,430,323 | 3,836,665 | -54.5% | $947.3K |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,713,331 | 2,352,360 | +37.3% | $580.8K |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 93,984 | 1,838,390 | +1856.1% | $452.2K |
| STATE STREET CORP | ADD | 1,355,583 | 1,694,783 | +25.0% | $418.4K |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 251,900 | 397,100 | +57.6% | $98.0K |
| GROUP ONE TRADING LLC | TRIM | 500,179 | 340,305 | -32.0% | $84.0K |
| CAPTRUST FINANCIAL ADVISORS | DOUBLED | 29,255 | 268,755 | +818.7% | $66.4K |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 45,300 | 72,000 | +58.9% | $21.6K |
| Russell Investments Group, Ltd. | ADD | 50,357 | 68,778 | +36.6% | $17.0K |
| Rockefeller Capital Management L.P. | DOUBLED | 2,900 | 7,900 | +172.4% | $2.0K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 22 transactions. Net -$106.9K — $0.00 bought, $106.9K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 25, 2026 | Davis Gregory D | Head of Research & Technology | TAX W/H | 1,630 | $0.1743 | $284.11 |
| May 25, 2026 | Jain Nikunj | Principal Accounting Officer | TAX W/H | 1,919 | $0.1743 | $334.48 |
| May 25, 2026 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | TAX W/H | 4,036 | $0.1743 | $703.47 |
| May 25, 2026 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | TAX W/H | 4,036 | $0.1743 | $703.47 |
| May 25, 2026 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | TAX W/H | 12,613 | $0.1743 | $2.2K |
| Apr 22, 2026 | Davis Gregory D | Head of Research & Technology | SELL | 69,827 | $0.2534 | $17.7K |
| Apr 21, 2026 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | SELL | 345,942 | $0.2578 | $89.2K |
| Apr 1, 2026 | Jain Nikunj | Principal Accounting Officer | AWARD | 225,000 | — | — |
| Apr 1, 2026 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | AWARD | 2,500,000 | — | — |
| Apr 1, 2026 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | AWARD | 800,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SGMO.
Shares short
24,769,059
Settlement Jun 15, 2026
Change vs prior
+0.8%
Semi-monthly cycle
Days to cover
4.1
At avg daily volume
All SGMO filing & press-release reports (5)
- 8-K reportJul 1, 2026
- 8-K reportApr 29, 2026
- CLUSTER reportApr 23, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 19, 2026